High-dose chemotherapy for adult and pediatric solid tumors has become a widespread treatment modality, despite the lack of mature phase III randomised studies, which are anyway presently undergoing throughout the EBMT Community. The EBMT Solid Tumors Registry includes (Ȱ October 25 th 1998) 10325 patients, 6633 adults (median age 30 Ϯ 18, range 0-76) and 3692 pediatric, (i.e. Յ18 years of age at the time of transplantation): breast carcinoma 4103, neuroblastoma 1603, germ cell tumors 1167, Ewing's sarcoma and PNET 773, CNS tumors, soft tissues sarcoma 592, ovarian carcinoma 486, Wilms' tumors 134. For patients grafted and reported in 1997, toxic death rate (Յ100 days from graft) was 3% (adults 3% and pediatric 4%); in particular for breast carcinoma pts 2%, for neuroblastoma pts 4% and for germ cell tumors pts 7%. 98% of adults and 82% of pediatric patients received PBPCT in 1997, while only 5% had ABMT (alone or in combination with PBPC) as hematologic rescue Ϯ CSF. Disease-free survival (DFS) among 2009 women with metastatic breast cancer was 33% at 3 years, with much better results for those transplanted in CR1 (first complete remission): nearly 50% projected at 3 years. In the adjuvant setting median DFS has not been reached with extremely interesting results for patients with Ͼ20 positive axillary nodes (54% at 3 years), which bear a very dismal prognosis with standard therapy (Յ25%). For neuroblastoma (1603 pts) the curve has not reached a plateau, even if 184 pts are alive at 5 years from graft, but late relapses still occur.A well update Registry forms the basis of possible clinical studies and several are ongoing on behalf of the EBMT (Pegase 01, 03, 05, EBDIS, OVCAT, IT94, random ICE). S192 S193
